Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy

Overview of attention for article published in Molecular Therapy, January 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter: 6 X users
patent: 6 patents

f1000: 1 research highlight platform

Readers on

mendeley: 65 Mendeley

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 8,707 followers.

RT @DrValFajardo: More evidence for targeting SERCA for mdx cardiomyopathy: https://t.co/sSnzNRZJx1

More evidence for targeting SERCA for mdx cardiomyopathy: https://t.co/sSnzNRZJx1

RT @NeuroGen_papers: PubMed: Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular…

PubMed: Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy. https://t.co/rRPRyzA0X5

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.